The burden of the articles is that investors will be cautious until CTIC's management proves it can deliver. The article also contains an interesting method to compare biotech valuations.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.